"Fingolimod Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068876
|
| MeSH Number(s) |
D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350
|
| Concept/Terms |
Fingolimod Hydrochloride- Fingolimod Hydrochloride
- Hydrochloride, Fingolimod
- 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Fingolimod Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Fingolimod Hydrochloride".
This graph shows the total number of publications written about "Fingolimod Hydrochloride" by people in this website by year, and whether "Fingolimod Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fingolimod Hydrochloride" by people in Profiles.
-
Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis. Int J Mol Sci. 2019 Oct 11; 20(20).
-
The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J. 2019 06; 33(6):7647-7666.
-
Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation. Neurochem Res. 2017 Oct; 42(10):2755-2768.
-
Effects of fingolimod administration in a genetic model of cognitive deficits. J Neurosci Res. 2017 05; 95(5):1174-1181.
-
AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis. PLoS One. 2015; 10(10):e0141781.
-
FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans. Lipids Health Dis. 2015 Jul 04; 14:66.
-
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.
-
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Sep 12; 122(11):1923-34.
-
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013 01; 5(1):105-21.
-
Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. Neurochem Res. 2012 Jun; 37(6):1154-69.